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Human Food Safety Implications 
of Variation in Food Animal Drug 
Metabolism
Zhoumeng Lin1, Christopher I. Vahl2 & Jim E. Riviere1
Violative drug residues in animal-derived foods are a global food safety concern. The use of a fixed main 
metabolite to parent drug (M/D) ratio determined in healthy animals to establish drug tolerances and 
withdrawal times in diseased animals results in frequent residue violations in food-producing animals. 
We created a general physiologically based pharmacokinetic model for representative drugs (ceftiofur, 
enrofloxacin, flunixin, and sulfamethazine) in cattle and swine based on extensive published literature. 
Simulation results showed that the M/D ratio was not a fixed value, but a time-dependent range. 
Disease changed M/D ratios substantially and extended withdrawal times; these effects exhibited drug- 
and species-specificity. These results challenge the interpretation of violative residues based on the use 
of the M/D ratio to establish tolerances for metabolized drugs.
The cornerstone of regulatory chemical food safety programs is the monitoring of food products for violative 
chemical residues. For edible products from food-producing animals, such as meat, milk or eggs, residue concen-
trations are determined based on jurisdictional-specific regulations that result in the determination of a tolerance 
(TOL) or maximum residue level (MRL) for specific drugs in a specific tissue for specific animal species1. These 
are based on toxicological assessments related to consumption of meat containing the specific drug in the diet 
coupled to a safety factor that accounts for uncertainty which yields the acceptable daily intake (ADI). These cal-
culations using laboratory animal dietary toxicity studies to determine no observed adverse effect levels are based 
on exposure to total drug, which is the sum of parent drug and metabolites. From this total ADI, food consump-
tion is used to calculate what the TOL or MRL for total drug exposure in so-called target tissues (e.g., liver, kidney, 
muscle). When the drug under question is metabolized in the food animal species, a ratio is established very early 
in the drug development process between total drug and the “marker residue”, which would be monitored for 
analytical determination in tissue testing. The marker residue could be either the parent drug or a metabolite. The 
legal TOL and MRL are then expressed in terms of this marker residue.
There are a number of potential issues surrounding the use of a marker residue and determination of the 
main metabolite to parent drug (M/D) ratio (a surrogate of the ratio of the marker residues to total residues). 
These include: (i) the ratio is determined in a very early study for limited early time points in a small number of 
animals and usually assumed as a fixed parameter, (ii) the studies are done in healthy animals, but the drug is 
used in diseased animals, and (iii) the final formulation is not employed. Subsequent studies are then conducted 
employing this fixed ratio in larger number of healthy animals to determine a withdrawal time after cessation of 
drug administration that will deplete target tissues to below the TOL or MRL for the marker residue. Due to these 
flaws, violative drug residues in the edible tissues of food-producing animals may occur when drugs are used in 
an extralabel manner or when disease is present even though the animals are slaughtered according to regulatory 
labeled withdrawal times2,3. Commonly reported drug violations include ceftiofur, enrofloxacin, flunixin, and 
sulfamethazine4. As a result, drug residue violation in food animals has become a global food safety concern5,6.
The focus of this study is to provide systematic evidence that the use of a fixed M/D ratio in the calculation 
of TOL (or MRL) and withdrawal times is fundamentally flawed. We hypothesized that changes in the rate and 
extent of drug metabolism due to disease or species (or even breed) differences could alter this ratio, tissue res-
idue levels and withdrawal times, making the marker residue a poor indicator of tissue exposure to unsafe drug 
concentrations.
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Results
Calibration of a general physiologically based pharmacokinetic (PBPK) for multiple drugs in 
two food animal species. To predict the M/D ratio and evaluate how possible change of this ratio by dis-
ease is related to drug withdrawal times, we established a general PBPK computational model for several com-
monly reported residue-violative drugs (ceftiofur, enrofloxacin, flunixin, and sulfamethazine) in cattle and swine 
(Fig. 1). The model was calibrated for each chemical in each species with multiple datasets from the Food Animal 
Residue Avoidance Databank (FARAD) (listed in Supplementary Table 1). All model parameters are provided 
in Supplementary Tables 2–6 and details of model development refers to Methods. Results of regression anal-
yses between model-simulated and measured plasma and tissue concentrations of parent drugs and/or major 
metabolites for each drug in each species are shown in Fig. 2. All determination coefficient R2 values were ≥ 0.89, 
indicating excellent overall goodness-of-fit for all simulations. Comparisons of the time course of model-simu-
lated versus measured concentration data are shown in Supplementary Fig. 1 (ceftiofur in cattle), Supplementary 
Fig. 2 (ceftiofur in swine), Supplementary Fig. 3 (enrofloxacin in cattle), Supplementary Fig. 4 (enrofloxacin in 
swine), Supplementary Fig. 5 (flunixin in cattle), Supplementary Fig. 6 (flunixin in swine), Supplementary Fig. 7 
(sulfamethazine in cattle), and Supplementary Fig. 8 (sulfamethazine in swine). Overall, the model-simulated 
concentrations correlated with the measured data very well for all selected drugs in both species.
Evaluation of the PBPK model with independent data. The model was further employed to simulate 
other pharmacokinetic studies not used in the model calibration process (Supplementary Table 1). As shown in 
Supplementary Fig. 9, all R2 values for the regression analyses between model-predicted and measured data were 
≥ 0.76, suggesting adequate goodness-of-fit. These model evaluation results suggest that our model can be used 
to predict the concentrations of studied drugs and/or their metabolites in the plasma and tissues of cattle and 
swine with an acceptable accuracy. Model sensitivity analyses were also performed and the results are presented 
in Supplementary Table 7.
PBPK model-predicted M/D ratios of studied drugs exhibit a wide range, depend on multiple 
factors, and correlate with experimental data well. After model validation, we applied the model to 
predict the M/D ratios of studied drugs and compared the predicted results to measured data (reported M/D ratio 
data for studied drugs are shown in Supplementary Table 8). The results showed that simulated M/D ratios for 
enrofloxacin, flunixin, and sulfamethazine had a wide range and were dependent on the species, drug, exposure 
route, tissue, and time, which correlated with experimental data very well (Supplementary Fig. 10). For example, 
the M/D ratios for enrofloxacin in the plasma of cattle after IV injection (5 mg/kg) was ~0.1–10, but these ratios 
were generally < 0.2 in the plasma of swine exposed to the same dose of enrofloxacin via the same route. Within 
the same species, the M/D ratios were very close in the plasma of swine exposed to 5 mg/kg enrofloxacin via IV 
versus to 10 mg/kg orally, but the M/D ratios were about 2-fold different between subcutaneous (SC) and IV 
exposures to the same dose of flunixin (2.2 mg/kg). The M/D ratios for sulfamethazine kept changing during 
Figure 1. A schematic of a general physiologically based pharmacokinetic (PBPK) model for drugs 
approved in food animals that have more than one metabolite in the body. PBPK models for several 
representative drugs, including ceftiofur, enrofloxacin, flunixin and sulfamethazine, in cattle and swine were 
developed and evaluated in this study. IV, IM, SC, and oral represent drug administration through intravenous, 
intramuscular, subcutaneous injection, and oral route (gavage or feed), respectively.
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the absorption phase (≤ 168 h) and the distribution phase (168–200 h), but it seemed to be constant during the 
terminal phase (≥ 200 h) in the plasma or tissues of swine after a 7-day consecutive oral exposure at 12-h intervals 
(Supplementary Fig. 10). In addition, the M/D ratios in the kidney were ~5-fold higher than in the muscle of 
swine after 7-day oral exposure to sulfamethazine.
Disease changes the M/D ratio substantially and the degree of changes depends on the drug, 
exposure time, tissue and species. Next, we employed the model to predict the M/D ratio and tissue res-
idues of studied drugs in the plasma and tissues in each species in both healthy and diseased animals after expo-
sure to representative labeled therapeutic paradigms. Information about labeled therapeutic regimens, marker 
residues, target tissues, withdrawal times, and TOL of studied drugs is provided in Supplementary Table 9. The 
Figure 2. Regression analysis results of PBPK model calibration datasets. PBPK models for ceftiofur (A,B), 
enrofloxacin (C,D), flunixin (E,F), and sulfamethazine (G,H) in healthy cattle and swine were developed based 
on datasets listed in Supplementary Table 1. Each panel represents the result of a regression analysis between 
model-simulated and measured plasma and/or tissue drug concentrations for each drug in each species. R2 values 
and regression lines are shown in each panel. PD: concentrations of the parent drug; Met: concentrations of the 
main metabolite; PD+ Met: concentrations of parent drug plus its major metabolite.
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results showed that disease altered the M/D ratio substantially, regardless of the drug, administration regimen, 
exposure time, species, and tissue (Fig. 3 and Table 1). The degree of alterations varied depending on the drug, 
exposure time, tissue, and species. In general, disease changed the M/D ratios of ceftiofur, enrofloxacin, flunixin, 
and sulfamethazine by several (i.e., 2–6) fold and the M/D ratio could be different by up to several orders of mag-
nitude at the withdrawal time compared to that at the time right after drug administration (the first simulation 
time was at 0.1 h after drug administration). For example, diseased changed the plasma M/D ratio of ceftiofur 
in cattle by 2-fold and in swine by 3-fold at 0.1 h after drug administration, and diseased altered the plasma 
M/D ratio of sulfamethazine by ~5.5-fold in cattle and by ~3-fold in swine at the withdrawal time. Note that for 
ceftiofur the model-predicted M/D ratios at the withdrawal time could not be accurately estimated (i.e., > 1020) 
because ceftiofur’s metabolic transformation was so rapid that at the withdrawal time, the residue was essentially 
all metabolites (Table 1).
Disease affects the tissue residue levels and estimated withdrawal times in a drug- and 
species-dependent manner. The PBPK model-simulated results also showed that disease affected the 
drug tissue marker residue levels, which in turn impacted the withdrawal time estimation, but this effect was 
Figure 3. Effect of disease on the main metabolite to parent drug (M/D) ratio. Healthy and diseased cattle 
and swine were assumed to be exposed to labeled therapeutic regimens of ceftiofur (A,B), enrofloxacin (C,D), 
flunixin (E,F), and sulfamethazine (G,H). The M/D ratios of studied drugs in the plasma and tissues of cattle 
and swine were predicted using the PBPK model. The labeled therapeutic regimens of these drugs are shown in 
Supplementary Table 9.
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dependent on the drug and species (Fig. 4). Specifically, disease did not (or minimally) affect the concentration of 
ceftiofur marker residue (its main metabolite desfuroylceftiofur) in the cattle and swine. Disease did not change 
the concentration of the marker residue of enrofloxacin (its main metabolite ciprofloxacin) in cattle, either, but 
the enrofloxacin marker residue in swine is the parent drug and its concentrations were considerably altered by 
disease. As a result, the withdrawal time for enrofloxacin in diseased swine should be extended by at least 1 day 
(Fig. 4). The marker residue for flunixin and sulfamethazine in both species is the parent drug itself. Disease 
substantially changed the marker residues of flunixin and sulfamethazine in the target tissues of both cattle and 
swine. Consequently, based on the data used in these simulations, the withdrawal time should be prolonged by 3 
days for flunixin in cattle, by 11 days for flunixin in swine, by 4 days for sulfamethazine in cattle, and by 12 days 
for sulfamethazine in swine (Fig. 4). These results suggest that the withdrawal time can be substantially length-
ened due to disease for certain drugs (e.g., flunixin and sulfamethazine) with the parent compound as the marker 
residue. Therefore, it is scientifically flawed to label withdrawal times determined in healthy animals for use in 
diseased animals.
Discussion
The model simulations suggest that the M/D ratio is not a fixed value, but has a wide range, depending on mul-
tiple factors, including the drug, exposure time, species, and disease state. This finding is important because it 
challenges the fundamental assumption of using a fixed point estimate for the M/D ratio used in the current US 
FDA guideline for evaluating the safety of compounds in food-producing animals1. According to this guideline, 
a marker residue is a residue whose concentration is in a known relationship to the concentration of the total 
residue in the last tissue to deplete to its permitted concentration1. The marker residue can be the parent drug, 
any of its metabolites (usually the main metabolite), or a combination of the residues. Our data clearly show that 
this relationship is not a fixed point estimate, but rather varies over a wide range because of the numerous factors 
influencing it. In particular, our data demonstrate that the M/D ratio can be different by several fold to several 
orders of magnitude at the withdrawal time compared to that at the time right after drug administration and dis-
ease and route of administration can change the M/D ratio by several fold in both plasma and tissues regardless 
of the drug or species. Thus, the withdrawal time calculated based on a fixed M/D ratio in healthy animals is not 
appropriate for diseased animals.
It should be noted that the drawback of using a ratio involving metabolites to determine a withdrawal/detec-
tion time has already been challenged in other fields, such as doping control in horses7. The influence of diseases 
on the disposition of veterinary drugs and the resulting consequences on withdrawal time has been acknowl-
edged for several decades8. The strength of the present study is to provide a broader-based quantitative estimate 
of the magnitude of this effect based on PBPK model simulations involving multiple veterinary drugs in two 
commonly used food animal species. Overall, our results strongly suggest that the current FDA guideline on the 
withdrawal time determination1 may need to be revised.
Drug Species Status
Plasma Liver Kidney Muscle
0.1 h WDT 0.1 h WDT 0.1 h WDT 0.1 h WDT
Ceftiofur* 
Cattle
Healthy 0.32 Indeterminant 1.15 Indeterminant 0.28 Indeterminant 0.27 Indeterminant
Diseased 0.15 Indeterminant 0.37 Indeterminant 0.13 Indeterminant 0.12 Indeterminant
Swine
Healthy 0.026 Indeterminant 0.079 Indeterminant 0.023 Indeterminant 0.02 Indeterminant
Diseased 0.0089 1328579 0.026 1367886 0.008 1306966 0.007 1323341
Enrofloxacin
Cattle
Healthy 0.046 0.91 0.21 1.51 0.011 0.24 0.02 0.91
Diseased 0.017 0.38 0.067 0.5 0.004 0.1 0.0076 0.38
Swine
Healthy 0.0022 0.18 0.018 0.25 0.00013 0.012 0.00061 0.18
Diseased 0.00075 0.048 0.0062 0.066 0.000044 0.003 0.00021 0.048
Flunixin
Cattle
Healthy 0.018 0.093 0.024 0.089 0.00019 0.0017 0.004 0.07
Diseased 0.0061 0.029 0.008 0.027 0.000066 0.0005 0.0014 0.02
Swine
Healthy 0.00074 0.012 0.0032 0.013 0.0000064 0.00026 0.00011 0.0091
Diseased 0.00025 0.004 0.0011 0.004 0.0000021 0.000086 0.000038 0.003
Sulfamethazine
Cattle
Healthy 0.038 1.15 0.018 0.58 0.06 1.89 0.011 0.19
Diseased 0.013 0.21 0.006 0.1 0.02 0.34 0.0037 0.035
Swine
Healthy 0.0081 0.13 0.021 0.34 0.018 0.4 0.0068 0.13
Diseased 0.0026 0.039 0.007 0.099 0.0059 0.12 0.0022 0.039
Table 1.  Main metabolite to parent drug (M/D) ratios of ceftiofur, enrofloxacin, flunixin, and 
sulfamethazine in healthy and diseased cattle and swine. Note: WDT represents the withdrawal time. The 
withdrawal time is dependent on the formulation of the drug. In this table, M/D ratios represent the model-
predicted M/D ratios at the first simulation time point (0.1 h) and at withdrawal times after exposure to labeled 
therapeutic regimens of studied drugs. The labeled therapeutic regimens and associated withdrawal times of 
these drugs are shown in Supplementary Table 9. * “Indeterminant” indicates that the model-predicted M/D 
ratios at the withdrawal time could not be accurately estimated (i.e., > 1020) since the metabolic transformation 
for ceftiofur was so rapid that at the withdrawal time, the residue was essentially all metabolites.
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The fact that the M/D ratio is altered substantially due to disease is mainly because disease changes the hepatic 
metabolism of drugs. The extent of changes in the M/D ratio depends on the severity of the disease. The present 
study assumed an average 3-fold change in hepatic metabolic rate based on the available published pharma-
cokinetic studies in diseased animals (further justified in Methods)2,9,10. It should be noted that in reality some 
animals may have very severe diseases and the extent of changes in hepatic metabolism may be greater, which, in 
turn, may alter the M/D ratio and withdrawal time even more. Additionally, hepatic metabolism of studied drugs 
was described using a linear equation because their metabolism is generally not saturated at therapeutic doses 
(justified in Methods). However, if saturation occurs, the M/D ratios might be even skewed more.
Besides diseases, other factors, such as genetic polymorphisms, breed differences, the type of food, drug-drug 
interaction, and feedlot environment, may also affect M/D ratios and withdrawal times11–14. Recent studies have 
proposed population-based approaches, either population mixed-effect pharmacokinetic15,16 or population 
PBPK modeling17,18, to estimate withdrawal times of veterinary drugs in food animals because population-based 
approaches are stochastic modeling techniques that can consider all possible factors and incorporate all available 
data into analysis. Population-based analysis of the present PBPK models was not performed because the focus 
Figure 4. Effect of disease on the tissue residue and withdrawal time. Healthy and diseased cattle and swine 
were assumed to be exposed to labeled therapeutic regimens of ceftiofur (A,B), enrofloxacin (C,D), flunixin 
(E,F), and sulfamethazine (G,H). The concentrations of marker residues of studied drugs in the target tissue 
were predicted using the PBPK model. The predicted marker residue concentrations were compared to the 
tolerances (red solid lines) of studied drugs in each species. The labeled therapeutic regimens of studied drugs 
are shown in Supplementary Table 9.
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on this work was to evaluate the M/D ratio variation and how it was affected by disease. Nevertheless, the present 
model provides a foundation for population-based analysis, which is a future objective.
Another merit of this study is the creation of a general multi-route PBPK model for multiple drugs from 
different use classes, including cephalosporins (ceftiofur), fluoroquinolones (enrofloxacin), nonsteroidal 
anti-inflammatory drugs (flunixin), and sulfonamides (sulfamethazine) across two common food animal spe-
cies. This modeling strategy represents a significant advance in this field because published PBPK models for 
veterinary drugs all focus on a single drug or one species18–23. These available models have different model 
structures that prevent direct comparisons of the pharmacokinetics of different drugs across species. It is also 
time-consuming, expensive, and may be unrealistic to develop individual models for each drug because there are 
numerous drugs in the market. In this regard, the use of a general model is crucial because it allows to compar-
ing pharmacokinetic parameters of various drugs between species. A general model also makes it economically 
affordable and technically more feasible to assess M/D ratios and withdrawal times of multiple drugs using PBPK 
modeling approach. Successful validation of the present model in two food animal species suggest that this model 
can also be extrapolated to other food animal species, such as goat, sheep, and poultry. Therefore, the present 
model represents a novel and useful tool in veterinary pharmacometrics and will increase the application of PBPK 
modeling in veterinary medicine and food safety.
As discussed above, our simulation data also bring into question the toxicological interpretation of violative 
tissue residues in food safety surveillance programs determined using TOL or MRL of drugs known to be metab-
olized in food animals. The determination of actual risk to human consumption of these violative residues is 
calculated based on total drug, and must be interpreted in the context of flawed assumption of a fixed M/D ratio, 
which could suggest violation of the marker residue, despite safe total drug concentrations and thus no real risk 
to the consumer. This also illustrates the complexity facing regulators for determining TOL and/or withdrawal 
times for heavily metabolized pesticides in food-producing animals, which are currently not available and need 
to be established. The present study provides a framework for extrapolating to environmental contaminants (i.e., 
pesticides), other drugs, and to other species.
In summary, the present study demonstrated that the M/D ratio of studied drugs (ceftiofur, enrofloxacin, 
flunixin, and sulfamethazine) was not a fixed value, but rather varied over a wide range and was dependent on 
numerous factors, including disease, species, drug, tissue, exposure route, and time using a newly established 
general PBPK model. These results raise a question about the reasonableness of the underlying assumption of 
using a fixed M/D ratio parameter by FDA to determine TOL and withdrawal times of veterinary drugs in food 
animals. Nevertheless, it should be acknowledged that although the FDA method for calculating withdrawal 
times assumes that the M/D ratio is fixed and requires residue depletion studies be conducted in healthy animals, 
it is a relatively conservative estimate because the tolerance limit requires that 99% of the treated population will 
have residues below the tolerance at the labeled withdrawal time with a 95% confidence1. Further studies that 
utilize the present model framework and the proposed population-based modeling techniques are warranted to 
provide more reasonable estimates of drug withdrawal times that reflect actual field conditions of drug use to aid 
regulatory decisions on food safety.
Methods
Experimental data source. Pharmacokinetic data for ceftiofur, enrofloxacin, flunixin, and sulfamethazine 
in healthy and diseased cattle and swine after intravenous (IV), intramuscular (IM), subcutaneous (SC), or oral 
exposure were obtained from the Food Animal Residue Avoidance Databank (FARAD) comparative pharma-
cokinetic database, a USDA-supported initiative in veterinary medicine24,25. Key information of selected studies is 
provided in Supplementary Table 1. All data were extracted from selected studies using WebPlotDigitizer (version 
3.8, http://arohatgi.info/WebPlotDigitizer/). Only data from the heathy animals and values above the limit of 
quantification (generally LOQ ≥ 0.1 μ g/ml) were used for model calibration and evaluation.
Model structure. The model structure for ceftiofur, enrofloxacin, flunixin and sulfamethazine was designed 
to include two sub-models for the parent drug and the major metabolite, respectively, with each sub-model con-
sisting of 7 compartments, including the plasma, liver, kidney, muscle, fat, lung, and rest of body (Fig. 1). The 
other minor metabolites were pooled together and modeled as a single compartment. The liver, kidney, muscle 
and fat were modeled as individual compartments because these organs are common edible tissues and relevant 
to food safety. Plasma was included as it is the essential compartment linking all other compartments through sys-
temic circulation. The lung was considered as one compartment because many drugs are used to treat pneumonic 
infections, for which the lung is the target organ of interest. Additionally, it was necessary to include a lumped 
compartment to account for disposition of the drug and its metabolite to the rest of body. All compartments were 
assumed to be blood flow-limited and well-stirred.
In order to develop a general PBPK model, common drug administration routes, including IV, IM, SC, and 
oral (gavage or via feed) exposures were included in the model. Note that besides therapeutic administrations via 
IV, IM, SC and oral routes, other causes of drug tissue residues include management practices, feed supplies, and 
recycling through bedding, which are important confounding factors for the establishment of a withdrawal time 
in doping control and is relevant to drug tissue residue violation (especially for drugs extensively eliminated by 
renal clearance)11. However, the contribution of drug concentrations from these other causes are almost negligible 
compared to that from therapeutic administrations. Therefore, these other possible exposure sources, such as 
through recycling of bedding, were not included in the present PBPK model.
Plasma protein binding of parent drugs and their main metabolites was simulated based on experimentally 
measured fixed ratio values20,26,27. Elimination pathways included hepatic metabolism of parent drugs, urinary 
excretion of parent drugs and their metabolites via the kidney. Since selected drugs have multiple metabolites, 
a percentage parameter (i.e., Frac) was included as an initial estimate to represent the fraction of a parent drug 
www.nature.com/scientificreports/
8Scientific RepoRts | 6:27907 | DOI: 10.1038/srep27907
that is metabolized to form its major metabolite. The metabolic and excretory processes were described using 
first-order linear equations22,28. The therapeutic dose window of veterinary drugs is typically narrow and their 
metabolism is generally not saturated at therapeutic doses, so a linear equation is often sufficient and commonly 
used to simulate metabolism of veterinary drugs in food animals18,22,23. The model was implemented using acslX 
software (Version 3.0.2.1, Aegis Technologies Group, Inc., Huntsville, AL). Equations and complete model code 
describing the absorption, plasma protein binding, distribution, metabolism, and elimination processes are pro-
vided and explained in the Supplementary Information. The complete model code will also be deposited on our 
website (http://iccm.k-state.edu/).
Model parameterization. Physiological parameters for cattle and swine were obtained from the litera-
ture18,20,22 and are provided in Supplementary Table 2. Initial values for partition coefficients were obtained from 
earlier PBPK models for flunixin and sulfamethazine20,22, or calculated using tissue:plasma AUC (area under the 
concentration curve) ratio method based on pharmacokinetic data in cattle for enrofloxacin29, or based on the 
reported tissue penetration factors for ceftiofur27. Initial values for partition coefficients of main metabolites were 
not available and thus were assumed to be the same or similar to their parent drugs. Partition coefficients and 
other drug-specific parameters (route-specific absorption rates, hepatic metabolic rates, fraction of drugs metab-
olized to main metabolites, and elimination rates) were then estimated using the parameter optimization module 
in acslX, followed by an iterative manual adjustment approach to obtain a visually reasonable fit to the experi-
mental data for model calibration. The chemical-specific parameter values are given in Supplementary Tables 3–6.
Model evaluation. The goodness-of-fit of model predictions was evaluated by model convergence, visual 
inspection (i.e., whether the simulation result captures the kinetic profile of the experimental data), and determi-
nation coefficients (R2 values) of linear regression analyses between model-predicted and experimental data using 
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA)23. Importantly, multiple independent datasets were 
used to evaluate model prediction performance for each drug in each species (listed in Supplementary Table 1). 
The criterion of a validated model was based on World Health Organization (WHO) PBPK modeling guidelines, 
i.e., if the simulated values were generally within a factor of two of the measured data, the model was considered 
acceptable and validated30.
Sensitivity analysis. Sensitivity analysis was conducted to determine the effect of each parameter on critical 
model outputs, including 24-h AUC of plasma, liver, kidney, and muscle concentrations of parent drugs and main 
metabolites. The normalized sensitivity coefficient (NSC) was calculated using the following equation: NSC = 
Δ r/r * p/Δ p, where p is the initial parameter value, Δ p is 1% of the parameter value, r is the model output derived 
from the original parameter value, and Δ r is the change of model output due to 1% increase in the parameter 
value. Parameters with absolute values of NSC ≥ 0.5 were considered highly sensitive28.
Model application. To evaluate whether the M/D ratio is a fixed value, the models were employed to predict 
the M/D ratio for ceftiofur, enrofloxacin, flunixin and sulfamethazine in the plasma and/or tissues of cattle and 
swine. The M/D ratio was used as a surrogate for the ratio of the marker residues to the total drug residues (parent 
drug plus all metabolites). The predicted values were compared to experimental data shown in Supplementary 
Table 8. Measured M/D ratio for ceftiofur is not available because most pharmacokinetic studies of ceftiofur 
measure the concentration of total desfuroylceftiofur acetamide as a composite of free desfuroylceftiofur, des-
furoylceftiofur cysteine conjugate, plasma protein-bound desfuroylceftiofur, and a small fraction of other polar 
metabolites. There are no data measuring levels of both ceftiofur and its individual metabolites. Nevertheless, 
PBPK modeling made it possible to predict the M/D ratio for ceftiofur.
The present model can also be used to assess the effect of changes in the rate and extent of metabolism due to 
disease, genetic polymorphism, and/or breed/sex differences on the M/D ratios, tissue residue levels, and with-
drawal times of studied drugs. Numerous studies have shown that disease alters the pharmacokinetics of vari-
ous drugs2,10,15,31. The degree of pharmacokinetic changes depends on the severity of the disease. For example, 
chemical-induced acute hepatic or renal failure resulted in increased AUC and decreased clearance by ~2.2-fold 
in rats after IV administration of flunixin32. Nephrectomized rats had elevated AUC and reduced clearance by 
~40% after enrofloxacin IV injection33. Mastitic cows had ~2-fold increase in AUC and ~2-fold decrease in clear-
ance compared to healthy cows after IV flunixin administration2. Overall, a ~2-fold pharmacokinetic alteration 
was observed in diseased animals, and this change has been attributed to downregulation of hepatic and intestinal 
drug-metabolizing enzymes, such as ~40–85% decrease of total CYP450 activity34,35. Through iterative model 
simulations, it was found that a 3-fold decrease in the hepatic metabolism rate (Km [h−1]) was needed in order 
to achieve a 2-fold increase in model-predicted plasma AUC of the parent drug. Therefore, the model was used 
to assess the impact of 3-fold change of Km (designated as a general metabolic feature for diseased animals com-
pared to healthy animals) on the M/D ratios, tissue residues, and withdrawal times of studied drugs in both cattle 
and swine according to the labeled therapeutic regimens (Supplementary Table 9).
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